For clinically important hypotension resulting primarily from vasodilation in the…. ANDA 217521, held by Be Pharms. Phenylephrine Hydrochloride.
As of Nov 16, 2026, ANDA 217521 (Phenylephrine Hydrochloride), held by Be Pharms, was first approved by FDA on Jun 26, 2023, with 0 approved supplements and 0 published complete response letters.
Phenylephrine Hydrochloride Injection 10 mg/mL is indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation in the settings of anesthesia and septic shock.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 26, 2023 | Original application | Approved | None posted |
| Phenylephrine Hydrochloride10MG/ML (10MG/ML) · solution;intravenous | Phenylephrine Hydrochloride | Rx |
| Phenylephrine Hydrochloride50MG/5ML (10MG/ML) · solution;intravenous | Phenylephrine Hydrochloride | Rx |
| Phenylephrine Hydrochloride100MG/10ML (10MG/ML) · solution;intravenous | Phenylephrine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters